Pharmacotherapy in depressed children and adolescents

References

• Ambrosini PJ. 2000. A review of pharmacotherapy of major depression in children and adolescents. Psychiat Serv 51:627–633.
   PubMed Web of Science ®Google Scholar
• Andrade C, Bhakta SG, Singh NM. 2006. Controversy revisited: Selective serotonin reuptake inhibitors in paediatric depression. World J Biol Psychiatry 7:251–260.
   PubMed Web of Science ®Google Scholar
• Bailly D. 2008. Benefits and risks of using antidepressants in children and adolescents. Expert Opin Drug Saf 7:9–27.
   PubMed Web of Science ®Google Scholar
• Baldessarini RJ. 1989. Current status of antidepressants: clinical pharmacology and therapy. J Clin Psychiatry 50:117–126.
   PubMed Web of Science ®Google Scholar
• Bridge JA, Jyengar S, Salary CB, Barbe RP, Birmaher B, Pincus HA, . 2007. Clinical response and risk for suicidal ideation and suicide attempts in pediatric antidepressant treatment. J Am Med Assoc 297:1683–1696.
   PubMed Web of Science ®Google Scholar
• Campbell M, Cueva JE. 1995. Psychopharmacology in child and adolescent psychiatry: a review of the past seven years. Part II. J Am Acad Child Adolesc Psychiatry 34:1262–1272.
   PubMed Web of Science ®Google Scholar
• Carvalho AF, Cavalcante JL, Castelo MS, Lima MC. 2007. Augmentation strategies for treatment-resistant depression: a literature review. J Clin Pharm Ther 32:415–428.
   PubMed Web of Science ®Google Scholar
• Courtney DB. 2004. Selective serotonin reuptake inhibitor and venlafaxine use in children and adolescents with major depressive disorder: a systematic review of published randomized controlled trials. Can J Psychiatry 49:557–563.
   PubMed Web of Science ®Google Scholar
• Dugas M, Mouren MC, Halfon O, Moron P. 1985. Treatment of childhood and adolescent depression with mianserin. Acta Psychiatr Scand Suppl 320:48–53.
   PubMedGoogle Scholar
• Edwarts JG, Anderson I. 1999. Systematic review and guide to selection of selective serotonin reuptake inhibitors. Drugs 57:507–533.
   PubMedGoogle Scholar
• Emslie GJ, Rush AJ, Weinberg WA, Kowatch RA, Hughes CW, Carmody T, . 1997. A double-blind, randomized, placebo-controlled trial of fluoxetine in children and adolescents with depression. Ach Gen Psychiatry 54:1031–1037.
   PubMed Web of Science ®Google Scholar
• Emslie GJ, Heiligenstein JH, Wagner KD, Hoog SL, Ernest DE, Brown E, . 2002. Fluoxetine for acute treatment of depression in children and adolescents: a placebo-controlled, randomized clinical trial. J Am Acad Child Adolesc Psychiatry 41:1205–1215.
   PubMed Web of Science ®Google Scholar
• Emslie GJ, Findling RL, Yeung PP, Kunz NR, Li Y. 2007. Venlafaxine ER for the treatment of pediatric subjects with depression: results of two placebo-controlled trials. J Am Acad Child Adolesc Psychiatry 46:479–488.
   PubMed Web of Science ®Google Scholar
• Emslie GJ, Kennard BD, Mayes TL, Nightingale-Teresi J, Carmody T, Hughes CW, . 2008. Fluoxetine versus placebo in preventing relapse of major depression in children and adolescents. Am J Psychiatry 165:459–467.
   PubMed Web of Science ®Google Scholar
• Fegert JM, Herpertz-Dahlmann B. 2005. Serotoninwiederaufnahmehemmer im Kindes- und Jugendalter. Warnhinweise der Behörden, Analyseergebnisse und Empfehlungen. Nervenarzt 76:1330–1339.
   PubMedGoogle Scholar
• Fleischhaker CH, Herpertz-Dahlmann B, Holtkamp K, Mehler-Wex, Warke A, Schulz E, . 2003. Indikationsspektrum und Nebenwirkungen von “neuen” Antidepressiva im Rahmen eines multizentrischen Arzneimittelmonitorings – eine Pilotstudie. Lemkuhl U. Psychotherapie und Psychopharmakotherapie im Kindes- und Jugendalter. Göttingen: Vandenhoeck & Ruprecht.
   Google Scholar
• Gerlach M, Baving L, Fegert J. 2006. Therapie mit Lithium-Salzen in der Kinder- und Jugendpsychiatrie – Klinische Wirksamkeit und praktische Empfehlungen. Z Kinder- Jugendpsychiatrie 34:181–189.
   Google Scholar
• Gerlach M, Klampfl K, Mehler-Wex C, Warnke A. Besonderheiten der Therapie mit Psychopharmaka im Kindes- und Jugendalter. 2009. Gerlach M, Mehler-Wex C, Walitza S, Warnke A, Wewetzer C. Psychopharmaka im Kindes- und Jugendalter. 2nd. Wien, New York: Springer. 73–88.
   Google Scholar
• Haapasalo-Pesu KM, Vuola T, Lahelma L, Marttunen M. 2004. Mirtazapine in the treatment of adolescents with major depression: an open-label, multicenter pilot study. J Child Adolesc Psychopharmacol 14:175–184.
   PubMed Web of Science ®Google Scholar
• Hammad TA, Laughren T, Racoosin J. 2006. Suicidality in pediatric patients treated with antidepressant drugs. Arch Gen Psychiatry 63:332–339.
   PubMed Web of Science ®Google Scholar
• Hazell P, O'Connell D, Heathcote D, Robertson J, Henry D. 1995. Efficacy of tricyclic drugs in treating child and adolescent depression: a meta-analysis. Br Med J 310:897–901.
   PubMed Web of Science ®Google Scholar
• Hazell P, O'Connell D, Heathcote D, Henry D. 2002. Tricyclic drugs for depression in children and adolescents. Cochrane Database Syst Rev 2:CD002317.
   PubMedGoogle Scholar
• Jorm AF, Allen NB, O'Donnell CP, Parslow RA, Purcell R, Morgan AJ. 2006. Effectiveness of complementary and self-help treatments for depression in children and adolescents. Med J Aust 185:368–372.
   PubMed Web of Science ®Google Scholar
• Kölch M, Fegert JM. 2006. [Medical treatment of depression in children and adolescents] Prax Kinderpsychol Kinderpsychiatr 56:224–233 [Review, in German].
   Google Scholar
• Lane RM. 1996. Pharmacokinetic drug interaction potential of selective serotonin reuptake inhibitors. Int Clin Psychopharmacol Suppl 5:31–61, and Int Clin Psychopharmacol 1997;12:126.
   Google Scholar
• Laux G, Baumann P, Hiemke C. 2007. TDM group of the Arbeitsgemeinschaft Neuropsychopharmakologie und Pharmakopsychiatrie. Therapeutic drug monitoring of antidepressants – clinical aspects. J Neural Transm Suppl 72:261–267 [Review].
   PubMedGoogle Scholar
• Lind AB, Reis M, Bengtsson F, Jonzier-Perey M, Powell Golay K, . 2009. Steady-state concentrations of mirtazapine, N-desmethylmirtazapine, 8-hydroxymirtazapine and their enantiomers in relation to cytochrome P450 2D6 genotype, age and smoking behaviour. Clin Pharmacokinet 48:63–70.
   PubMed Web of Science ®Google Scholar
• Mandoki MW, Tapia MR, Tapia MA, Sumner GS, Parker JL. 1997. Venlafaxine in the treatment of children and adolescents with major depression. Psychopharmacol Bull 33:149–154.
   PubMedGoogle Scholar
• March JS, Silva S, Petrycki S, Curry J, Wells K, Fairbank J, . 2007. The Treatment for Adolescents With Depression Study (TADS): long-term effectiveness and safety outcomes. Arch Gen Psychiatry 64:1132–1143. Erratum in: Arch Gen Psychiatry 2008;65(1):101.
   PubMed Web of Science ®Google Scholar
• Masand PS, Gupta S. 2002. Long-term side effects of newer-generation antidepressants: SSRIs, venlafaxine, nefazodone, bupropion, and mirtazapine. Ann Clin Psychiatry 14:175–182.
   PubMedGoogle Scholar
• Mulrow CD, Williams JW Jr, Trivedi M, Chiquette E, Aguilar C, Cornell JE, . 1998. Treatment of depression – newer pharmacotherapies. Psychopharmacol Bull 34:409–795.
   PubMed Web of Science ®Google Scholar
• Papanikolaou K, Richardson C, Pehlivanidis A, Papadopoulou-Daifoti Z. 2006. Efficacy of antidepressants in child and adolescent depression: a meta-analytic study. J Neural Transm 113:399–415.
   PubMed Web of Science ®Google Scholar
• Pössel P, Hautzinger M. 2006. Effekte pharmakologischer und psychotherapeutischer Interventionen auf Depressionen bei Kindern und Jugendlichen. Z Kinder Jugendpsychiatr Psychother 34:243–255.
   PubMedGoogle Scholar
• Safer DJ, Zito JM. 2006. Treatment-emergent adverse events from selective serotonin reuptake inhibitors by age group: children versus adolescents. J Child Adolesc Psychopharmacol 16:159–169.
   PubMed Web of Science ®Google Scholar
• Schlamp D. 1999. Remergil in der Kinder- und Jugendpsychiatrie. Psychiatr Dialog 3:8–9.
   Google Scholar
• Schmauss M, Messer T. 2007. [Augmentation strategies for therapy resistant depression – a review]. Psychiatr Prax 34:165–174.
   PubMedGoogle Scholar
• Schulte-Markwort M, Richterich A, Forouher N. 2008. Affektive Störungen. Herpertz-Dahlmann B, Resch F, Schulte-Markwort M, Warnke A. Entwicklungspsychiatrie. Biopsychologische Grundlagen und die Entwicklung psychischer Störungen. 2nd. Stuttgart: Schattauer. 784–792.
   Google Scholar
• Simeon J, Nixon MK, Milin R, Jovanovic R, Walker S. 2005. Open-label pilot study of St. John's wort in adolescent depression. J Child Adolesc Psychopharmacol 15:293–301.
   PubMed Web of Science ®Google Scholar
• Smith D, Dempster C, Glanville J, Freemantle N, Anderson I. 2002. Efficacy and tolerability of venlafaxine compared with selective serotonin reuptake inhibitors and other antidepressants: a meta-analysis. Br J Psychiatry 180:396–404.
   PubMed Web of Science ®Google Scholar
• , Treatment for Adolescents With Depression Study (TADS) TeamMarch J, Silva S, Curry J, Wells K, Fairbank J, Burns B, . 2009. The Treatment for Adolescents With Depression Study (TADS): outcomes over 1 year of naturalistic follow-up. Am J Psychiatry 166:1141–1149.
   PubMed Web of Science ®Google Scholar
• Tsapakis EM, Soldani F, Tondo L, Baldessarini RJ. 2008. Efficacy of antidepressants in juvenile depression: meta-analysis. Br J Psychiatry 193:10–17.
   PubMed Web of Science ®Google Scholar
• Wagner KD. Pharmacotherapy for major depression in children and adolescents. 2005. Prog Neuropsychopharmacol Biol Psychiatry 29:819–826.
   PubMedGoogle Scholar
• Wagner KD, Ambrosini P, Rynn M, Wohlberg C, Yang R, Greenbaum MS, . 2003. Sertraline Pediatric Depression Study Group. Efficacy of sertraline in the treatment of children and adolescents with major depressive disorder: two randomized controlled trials. J Am Med Assoc 290:1033–1041.
   PubMed Web of Science ®Google Scholar
• Wagner KD, Robb AS, Findling RL, Jin J, Gutierrez MM, Heydorn WE. 2004. A randomized, placebo-controlled trial of citalopram for the treatment of major depression in children and adolescents. Am J Psychiatry 161:1079–1083.
   PubMed Web of Science ®Google Scholar
• Weller EB, Weller RA. 2000. Treatment options in the management of adolescent depression. J Affect Disord Suppl 1:23–28.
   Google Scholar